NASDAQ:NXTCNextCure Stock Price, Forecast & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NXTC shares have decreased by 75.0% and is now trading at $9.56.
View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.53) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.03. NextCure had a negative net margin of 65.22% and a negative return on equity of 8.79%.
View NextCure's earnings history.

9 equities research analysts have issued 12-month price targets for NextCure's stock. Their forecasts range from $11.00 to $87.00. On average, they anticipate NextCure's stock price to reach $32.70 in the next twelve months. This suggests a possible upside of 242.1% from the stock's current price.
View analysts' price targets for NextCure.

Media coverage about NXTC stock has been trending very positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NextCure earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about NextCure.

Some companies that are related to NextCure include Akero Therapeutics (AKRO), Humanigen (HGEN), VBI Vaccines (VBIV), Retrophin (RTRX), Arcus Biosciences (RCUS), Phathom Pharmaceuticals (PHAT), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), I-Mab (ARQT), Generation Bio (GBIO), BioXcel Therapeutics (BTAI), Aimmune Therapeutics (AIMT), Athenex (ATNX), Gossamer Bio (GOSS) and Stoke Therapeutics (STOK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Amgen (AMGN), Alibaba Group (BABA), CVS Health (CVS), Dicerna Pharmaceuticals (DRNA), UnitedHealth Group (UNH), Honeywell International (HON), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T) and Arena Pharmaceuticals (ARNA).

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure's stock is owned by many different retail and institutional investors. Top institutional investors include Jennison Associates LLC (1.69%), Matthews International Capital Management LLC (0.92%), Vident Investment Advisory LLC (0.20%), Vident Investment Advisory LLC (0.20%), Asymmetry Capital Management L.P. (0.18%) and SG Americas Securities LLC (0.12%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan.
View institutional ownership trends for NextCure.

NXTC stock was bought by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, Asymmetry Capital Management L.P., SG Americas Securities LLC, Swiss National Bank, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Bessemer Group Inc., and Virtus ETF Advisers LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan.
View insider buying and selling activity for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $9.56.

NextCure has a market capitalization of $263.09 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]